Evidence map›Paper›PMID 40641739›Full record

ArticleBiochemistry and biophysics reports2025

Melphalan improves toxicity of arsenic trioxide in adult T-cell leukemia/lymphoma cells.

Faeze Khodadadi, Mohammad Hadi Sadeghian, Zahra Delbari, Mohadese Kazemi, Hamide Koohpaykar, Fatemeh B Rassouli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Faeze KhodadadiCancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Hadi SadeghianCancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra DelbariImmunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohadese KazemiImmunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamide KoohpaykarDepartment of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fatemeh B RassouliNovel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a hematologic neoplasm with poor prognosis. Melphalan is an alkylating anti-cancer agent, and arsenic trioxide (ATO) is routine chemotherapy drug for ATLL with low response rate. Due to the significant challenge that chemoresistance poses in treating ATLL, we aimed to investigate the potential of melphalan to enhance the effects of ATO as a combinatorial treatment approach for ATLL. MT-2 cells were exposed to different concentrations of melphalan and ATO and viability was evaluated by alamarBlue assay. Upon IC

Indexed as

ABCG2Adult T-cell leukemia/lymphomaArsenic trioxideMelphalan

Identifiers

PMID40641739
PMCPMC12242463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.